Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06467773

TSPO-PET/MRI in Surveillance of Neuroinflammation in the Central Nervous System

An Oberservational Study of Utility of TSPO-PET/MRI Using the Radiotracer ([18F]-DPA-714) in Surveillance of Neuroinflammation in the Central Nervous System

Status
Recruiting
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
Tongji Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Central Nervous System (CNS) inflammation is an immune response activated in the brain and spinal cord by microglial cells and astrocytes, commonly occurring under conditions such as central nervous system ischemia, autoimmunity, infection, toxins, and trauma. Microglial cells, as the innate immune cells of the central nervous system, are responsible for driving the inflammatory response and play a crucial role in sensing environmental changes, responding to harmful stimuli, and engulfing dead neurons. They also present antigens to T lymphocytes, mediating interactions between the peripheral immune system and the central nervous system. Factors released by neuronal cells can either promote or inhibit inflammation, and monitoring the level of inflammation driven by microglial cells is essential for the diagnosis and treatment of central nervous system diseases. MRI is the primary imaging method for central nervous system inflammation, but it can be challenging to diagnose. PET/MR, a technology that integrates PET and MR imaging, provides high-quality diagnostic images and is valuable for the early detection, diagnosis, and assessment of central nervous system diseases. The radioactive ligand 18F-DPA-714 PET, targeting the translocation protein (TSPO), can visualize activated microglial cells, which may have a gain effect in detecting active central nervous system inflammation. This study aims to explore the application of 18F-DPA-714 PET/MR in the early diagnosis, treatment evaluation, and prognosis of central nervous system inflammation.

Conditions

Interventions

TypeNameDescription
RADIATIONRadiation: PET-MRI with [18F]-DPA-714Radiation: PET-MRI with \[18F\]-DPA-714

Timeline

Start date
2024-07-01
Primary completion
2029-06-01
Completion
2029-12-30
First posted
2024-06-21
Last updated
2025-04-08

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06467773. Inclusion in this directory is not an endorsement.